The Next Step for MRD in Myeloma? Treating MRD Relapse after First Line Treatment in the REMNANT Study
Hemato · 2020
DOI: 10.3390/hemato1020008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hemato, 2020. Verfasst von Anne-Marie Rasmussen und 2 weiteren Autor:innen. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Janssen Pharmaceuticals, Kreftforeningen, Celgene.
Abstract (Originalsprache)
The treatment approach for multiple myeloma (MM) has changed in recent years. After the approval of maintenance treatment after stem cell transplant in younger patients, the paradigm of continuous treatment is now prevailing in all clinical situations of myeloma. However, the best time to initiate relapse treatment is still unclear. With increased frequency of minimal residual disease (MRD) negativity, and the established clinical benefit of this finding, one of the large clinical questions in myeloma is how to approach MRD re-appearance. In this paper, we go through the MRD technology, existing and possible uses of MRD in the clinic, and data for early treatment before we introduce the design of the ongoing REMNANT study; a randomized study with early treatment of MRD relapse after first line treatment.
Förderung
- Janssen Pharmaceuticals
- Kreftforeningen
- Celgene
- The Norwegian Government
Zitieren
APA
Rasmussen, A., Askeland, F. B., & Schjesvold, F. (2020). The Next Step for MRD in Myeloma? Treating MRD Relapse after First Line Treatment in the REMNANT Study. Hemato. https://doi.org/10.3390/hemato1020008
Vancouver
Rasmussen A, Askeland FB, Schjesvold F. The Next Step for MRD in Myeloma? Treating MRD Relapse after First Line Treatment in the REMNANT Study. Hemato. 2020. doi:10.3390/hemato1020008
BibTeX
@article{Rasmussen2020,
author = {Rasmussen, Anne-Marie and Askeland, Frida Bugge and Schjesvold, Fredrik},
title = {The Next Step for MRD in Myeloma? Treating MRD Relapse after First Line Treatment in the REMNANT Study},
journal = {Hemato},
year = {2020},
doi = {10.3390/hemato1020008}
}
EUVIMED